TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19587528
Drug: Mtb72F/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtb72F/AS02A vaccine
Study: 19594547
Drug: Oral fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludarabine in combination with rituximab (375 mg/m² rituximab on day 1, 40 mg/m² oral fludarabine once daily on days 1-5 every 28 days for up to six cycles)
Study: 19594547
Drug: Oral fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludarabine in combination with rituximab
Study: 19594946
Drug: Steroid-sensitive (SS)
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sensitive (SS) patients
Study: 19597050
Drug: Systematic clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic clinical testing including cardiac magnetic resonance imaging, signal-averaged ECG, exercise testing, drug challenge, and selective electrophysiological testing.
Study: 19601706
Drug: Intra-articular Hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Hylan G-F 20 injections
Study: 19604722
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin with docetaxel) followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery
Study: 19605490
Drug: Modified vaccinia
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines
Study: 19608747
Drug: All preparative
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All preparative regimens with CD34(+) cell doses exceeding 4.5 x 10(6)/kg
Study: 19608747
Drug: Higher CD34(+)
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher CD34(+) cell doses
Study: 19615940
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally once daily on schedule 4-2 (4 weeks on treatment, 2 weeks off)
Study: 19616281
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily until disease progression
Study: 19620489
Drug: 32 or
Normalized name: Darvon Compound 32 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 or 36 Gy in 4-Gy fractions, given twice daily (36 Gy cohort with pure photons)
Study: 19620516
Drug: Acetyl-L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (1 g twice daily) for 24 weeks
Study: 19624460
Drug: Dalteparin injected
Normalized name: dalteparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin injected subcutaneously (s.c.) twice daily at a median dose of 90 (73-106) units kg(-1) per 12 h
Study: 19624460
Drug: Dalteparin injected
Normalized name: dalteparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin injected subcutaneously (s.c.) twice daily
Study: 19625715
Drug: Vi vaccine
Normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi vaccine (children aged 2-5 years)
Study: 19625715
Drug: Vi vaccine
Normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi vaccine (unvaccinated neighbors)
Study: 19625715
Drug: Vi vaccine
Normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi vaccine (overall residents in clusters)
Study: 19628656
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) for 18 months
Study: 19629020
Drug: Pharmaceutical antidepressants
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical antidepressants
Study: 19630971
Drug: Erythropoietin (epoietin-beta)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (epoietin-beta) at high doses (1,500 U/kg/day for three days) combined with quinine
Study: 19630971
Drug: Erythropoietin (epoietin-beta)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (epoietin-beta) at high doses combined with quinine
Study: 19635928
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of acid sphingomyelinase inhibitors (amitriptyline, trimipramine, desipramine, chlorprothixene, fluoxetine, amlodipine, sertraline)
Study: 19636002
Drug: Bevacizumab, capecitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, capecitabine, and radiation (50.4 Gy per 28 fractions, capecitabine 825 mg/m² orally twice daily on days of radiation, bevacizumab 5 mg/kg on days 1, 15, and 29, followed by maintenance gemcitabine 1 g/m² weekly for 3 weeks and bevacizumab 5 mg/kg every 2 weeks)
Study: 19636010
Drug: Dacetuzumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacetuzumab (2 mg/kg weekly for 4 weeks, with dose escalation up to 8 mg/kg)
Study: 19638905
Drug: Subcutaneous mastectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mastectomy with nipple-areola skin conservation
Study: 19641325
Drug: Rosiglitazone, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone, 4 mg daily for 6 months
Study: 19643318
Drug: MRI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI at 1.5-T with specific absorption rate limited to 2 W/kg; ICDs reprogrammed pre-MRI
Study: 19646269
Drug: Final version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Final version of the quantitative survey administered to all registered call takers
Study: 19648219
Drug: Bupropion and
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion and group therapy for 2 months
Study: 19648970
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 4.5 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Study: 19648970
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 6.0 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Study: 19648970
Drug: Topotecan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (various doses)
Study: 19651065
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant human thrombin (rThrombin) applied during surgical procedure (day 1)
Study: 19651065
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant human thrombin (rThrombin)
Study: 19652055
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice daily until tumor progression or unacceptable toxicity
Study: 19652067
Drug: Pralatrexate at
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate at a dose of 30 mg/m(2) weekly for 6 weeks every 7 weeks (MTD established in phase I/II study)
Study: 19652067
Drug: Pralatrexate at
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate at a dose of 135 mg/m(2) every other week
Study: 19652630
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (Type 6/11/16/18)
Study: 19663708
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine booster
Study: 19664754
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous daclizumab (8 mg/kg at baseline, 4 mg/kg at week 2, 2 mg/kg every 4 weeks for 52 weeks)
Study: 19664754
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous daclizumab
Study: 19666119
Drug: ET(A) antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ET(A) antagonist BMS187824 (5 mg/kg, i.v.) followed by IRL-1620 (5 microg/kg, i.v.)
Study: 19671016
Drug: Parenteral procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral procaine benzyl penicillin and an aminoglycoside
Study: 19671733
Drug: Oleandrin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleandrin treatment
Study: 19675988
Drug: Powered knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered knee prosthesis with two series-elastic actuators in an agonist-antagonist arrangement
Study: 19679883
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (20 mg, thrice weekly for up to 12 weeks)
Study: 19679883
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab (thrice-weekly, fractionated-dose)
Study: 19687399
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with porfimer sodium (2 mg/kg, injected intravenously 48 hours before treatment) and light at 630 nm (50 J/cm² for dysplasia and CIS, 75 J/cm² for carcinoma)
Study: 19687399
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with porfimer sodium
Study: 19689789
Drug: Neoadjuvant anti-estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant anti-estrogen therapy (Tamoxifen for premenopausal women, Letrozole for postmenopausal women)
Study: 19689789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who did not undergo preoperative anti-estrogenic treatment)
Study: 19690058
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m(2) b.i.d. for 2 weeks followed by capecitabine 575-650 mg/m(2) b.i.d. and cisplatin 20-25 mg/m(2) i.v. weekly during chemoradiotherapy
Study: 19696651
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy in acute HIV-1 infection
Study: 19696651
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy in recent HIV-1 infection
Study: 19696651
Drug: Baseline viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline viral load <100,000/ml
Study: 19696651
Drug: Baseline viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline viral load >100,000/ml
Study: 19697416
Drug: Preservative-free (PF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free (PF) hepatitis B vaccine
Study: 19697416
Drug: Preservative-containing (PC)
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-containing (PC) hepatitis B vaccine
Study: 19697416
Drug: Low-preservative (LP)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-preservative (LP) hepatitis B vaccine
Study: 19698816
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg, taken continuously for three 28-day intervals.
Study: 19700662
Drug: Cytotoxic T
Normalized name: Cytotoxic T-lymphocyte proteinase 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic T lymphocyte (CTL) therapy with specificity for Epstein-Barr virus (EBV) and adenovirus (5 x 10(6)-1.35 x 10(8) cells/m(2))
Study: 19700662
Drug: Cytotoxic T
Normalized name: Cytotoxic T-lymphocyte proteinase 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic T lymphocyte (CTL) therapy with specificity for adenovirus
Study: 19703299
Drug: Atomoxetine (0.5-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5-1.2 mg/kg/day)
Study: 19712979
Drug: Escitalopram, 10
Normalized name: Escitalopram, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 10 mg for 49 days
Study: 19712979
Drug: Escitalopram, 10
Normalized name: Escitalopram, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 10 mg after 1 week
Study: 19712979
Drug: Serum drug
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum drug levels and genetic polymorphisms (5HTTLPR and 5HT2a)
Study: 19713456
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2)
Study: 19714615
Drug: Belimumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (1, 4, 10 mg/kg) plus standard of care therapy (SOC)
Study: 19714615
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard of care therapy (SOC)
Study: 19718477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PTX3 and BNP
Study: 19720904
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1 through 21 of a 28-day cycle for six cycles, plus prednisone 30 mg/d during cycle 1, 15 mg/d during cycle 2, and 15 mg/d every other day during cycle 3.
Study: 19720904
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and prednisone combination therapy
Study: 19720915
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m(2) once weekly during postoperative weeks 2, 3, and 4) followed by concurrent Paclitaxel (30 mg/m(2)) and Cisplatin (20 mg/m(2)) once weekly during the last 3 weeks of RT (60 Gy over 6 weeks).
Study: 19720915
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Cisplatin with radiation therapy (RT).
Study: 19720923
Drug: Concurrent trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent trastuzumab and HER2/neu-specific vaccination
Study: 19721480
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (180 microg weekly) and ribavirin (800 mg daily) for 14 weeks
Study: 19723786
Drug: CBT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT monotherapy
Study: 19725960
Drug: pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide (75 mg/m2 during radiotherapy, 150-200 mg/m2 on days 1-5 of each 28-day cycle) with radiotherapy (60 Gy)
Study: 19725960
Drug: pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide with radiotherapy
Study: 19726437
Drug: Thrombectomy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy in patients treated with IIb/IIIa-inhibitors
Study: 19726763
Drug: GDC-0449 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0449 (150 mg per day)
Study: 19726763
Drug: GDC-0449 (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0449 (270 mg per day)
Study: 19726763
Drug: GDC-0449 (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0449 (540 mg per day)
Study: 19727007
Drug: Direct Renin
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Renin Inhibitors (DRIs)
Study: 19727007
Drug: Direct Renin
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Renin Inhibitors (DRIs) added to optimal heart failure treatment
Study: 19727007
Drug: Early generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early generation Direct Renin Inhibitors (DRIs)
Study: 19727007
Drug: Recent Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent Direct Renin Inhibitors (DRIs)
Study: 19728876
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion (VE) with 500 mL of synthetic colloid
Study: 19731330
Drug: Hydroxyurea (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (20 mg/kg/day for 2 years)
Study: 19738014
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir at 5 mg/kg of body weight for 5 days, followed by oral valganciclovir at 900 mg for 16 days, both twice daily with dose adjustment for renal function.
Study: 19740906
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor alpha inhibitors (TNFalpha) - infliximab (n=41), etanercept (n=13), adalimumab (n=6)
Study: 19750065
Drug: Computerized Decision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Decision Support System (CDSS) for MDD treatment
Study: 19750065
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for MDD treatment
Study: 19751237
Drug: Rituximab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (4 weekly doses)
Study: 19752530
Drug: Elevated uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated uric acid group (>6 mg/dl)
Study: 19752530
Drug: Normal uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal uric acid group (≤6 mg/dl)
Study: 19753491
Drug: Trypanocidal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trypanocidal treatment with benznidazole
Study: 19753491
Drug: Antitrypanosomal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitrypanosomal therapy with benznidazole
Study: 19755203
Drug: hsCRP≥6.5 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP≥6.5 mg/L
Study: 19755203
Drug: NTpro-BNP≥4302 pg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTpro-BNP≥4302 pg/mL
Study: 19755203
Drug: Na serum
Normalized name: GLYCERIN 10.82 g in 100 mL TOPICAL LIQUID [Bio DNA Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na serum level≤135 mEq/L
Study: 19755203
Drug: Sodium plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium plasma levels ≤135 mEq/L
Study: 19755203
Drug: Sodium plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium plasma levels ≤135 mEq/L + NTpro-BNP≥4302 pg/mL
Study: 19757984
Drug: Post-bronchodilator FEV(1)/FVC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator FEV(1)/FVC ratio < or = 0.70
Study: 19757984
Drug: Post-bronchodilator FEV(1)/FVC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator FEV(1)/FVC ratio > 0.70
Study: 19758095
Drug: Safe water
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe water storage vessels, hygiene education, and bleach for household water treatment (Cohort B)
Study: 19770418
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and perioperative INGN 201 gene therapy
Study: 19771508
Drug: Epirubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin and docetaxel (2 or 3 weekly intervals)
Study: 19771508
Drug: Post-treatment tumor
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment tumor cellularity
Study: 19773266
Drug: CD20 positivity
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD20 positivity over 20% in patients with WBC over 30x10(9)/L
Study: 19782361
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg per day for one year
Study: 19786468
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (enoxaparin or nadroparin)
Study: 19786468
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of heparin therapy longer than 9 days
Study: 19786617
Drug: (131)I-BC8 antibody
Normalized name: Anti-b1 antibody I-131
DrugBank: Tositumomab I-131 (DB17991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-BC8 antibody (Ab; BC8) plus fludarabine and 2 Gy total body irradiation
Study: 19786667
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/d plus bortezomib 1.0 mg/m(2)
Study: 19786927
Drug: Lotrafilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafilcon A lenses for monthly continuous wear (CW)
Study: 19788755
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care coordinators (CCCs) providing care every three months in clinics and monthly in the community; CCCs underwent intensive training and mentoring.
Study: 19788755
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with monthly clinic visits.
Study: 19789316
Drug: SGN-30 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-30 (4 mg/kg to 12 mg/kg, i.v. every 3 weeks for six doses, with potential for two additional courses)
Study: 19796996
Drug: Transoral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral endoscopic restrictive implant system
Study: 19799842
Drug: S. aureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. aureus conjugate vaccine (StaphVAX) comprised of capsular polysaccharides 5 and 8 (CP5, CP8)
Study: 19799842
Drug: S. aureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. aureus conjugate vaccine (StaphVAX)
Study: 19805455
Drug: rHuPH20-facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuPH20-facilitated subcutaneous rehydration
Study: 19806596
Drug: Sorafenib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib as adjuvant treatment